Slate Medicines to merge with Fulcrum Therapeutics and raise $245 million to advance migraine pipeline

The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.

Slate Medicines and Fulcrum Therapeutics have agreed to merge in an all-stock transaction that will take Slate public through Fulcrum’s Nasdaq listing, alongside approximately $245 million in committed private financing for the combined company.

The transaction provides Slate with public-market access and capital to advance its migraine-focused pipeline, led by anti-PACAP/VIP monoclonal antibody SLTE-1009, while existing Fulcrum shareholders will retain a minority interest in the combined business.

Field	Content
Alert Type	Deal
Companies	Slate Medicines; Fulcrum Therapeutics
Deal Type	All-stock merger / reverse merger with concurrent private financing
Asset or Company	Slate Medicines and its migraine and headache-disorder pipeline, led by SLTE-1009
Therapy Area(s)	Neurology; Migraine; Headache disorders
Technology or Modality	Monoclonal antibody targeting PACAP/VIP signalling
Deal Value	The transaction is accompanied by approximately $245 million in committed private financing from new and existing investors. This represents financing for the combined company rather than an acquisition price. Fulcrum shareholders are also expected to receive a pre-closing special cash dividend, subject to the transaction terms and cash available at closing.
Development Stage	Clinical stage; SLTE-1009 is in Phase I development
Geography	United States
What Happened	On 17 August 2026, Slate Medicines and Nasdaq-listed Fulcrum Therapeutics announced a definitive agreement to combine in an all-stock merger. The combined business will operate under the Slate Medicines name and focus on developing therapies for migraine and other headache disorders. Approximately $245 million in committed private financing will accompany the transaction. Existing Fulcrum shareholders are expected to receive a pre-closing special cash dividend and retain a minority ownership position in the combined company. The transaction remains subject to shareholder approval and other customary closing conditions.
Why It Matters	The transaction provides Slate with a route to the public markets and substantial additional financing for its clinical-stage migraine pipeline without pursuing a conventional IPO. Its lead programme, SLTE-1009, targets PACAP/VIP signalling, providing a mechanism distinct from the CGRP pathway targeted by several established migraine therapies, although its clinical differentiation remains to be demonstrated.
Supporting Context	Slate launched in 2026 with a $130 million Series A financing and licensed SLTE-1009 from DartsBio Pharmaceuticals. Fulcrum entered a strategic review after discontinuing development of sickle cell disease candidate pociredir following FDA feedback and subsequently implemented substantial workforce reductions to conserve cash.
Strategic Rationale	Slate gains Fulcrum’s Nasdaq-listed corporate structure and additional capital to fund its pipeline, while Fulcrum shareholders can receive a special cash dividend while retaining an economic interest in the combined company. The structure effectively redirects Fulcrum’s public-market vehicle towards Slate’s migraine-focused development strategy.
Potential Impact	The financing is intended to support continued development of SLTE-1009 and Slate’s broader headache-disorder pipeline. Whether the transaction establishes a differentiated migraine franchise will depend on clinical results from SLTE-1009 and subsequent programmes.
Key Takeaway	The Fulcrum merger gives Slate a Nasdaq-listed vehicle and $245 million of committed financing to advance its anti-PACAP migraine development strategy.
What to Watch	Completion of the merger and financing, the final value of Fulcrum’s special cash dividend and emerging clinical data for SLTE-1009 as Slate advances the programme beyond early-stage development.
Primary Source	Fulcrum Therapeutics and Slate Medicines transaction announcement / SEC filings
Relevant Date	17 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com